Universal Corporation Q4 FY2026 earnings call

• Executive Leadership Transition

  • Steven S. Diel, who has been with Universal since 2018 and has over 25 years of experience in finance, corporate development, and strategy, was appointed Chief Financial Officer effective April 1, 2026.
  • Diel's core priorities as CFO are to deliver dependable free cash flow, maintain a strong balance sheet through disciplined capital allocation, and drive long-term durable shareholder value across business cycles.

• Strategic Business Positioning

  • The core leaf tobacco business has over 100 years of operating experience, a market-leading position, broad geographic diversification, and long-standing customer relationships that have demonstrated durability across full market cycles.
  • The ingredients business strategy is focused on innovative, solution-based clean label, healthy, and organic products aligned with long-term customer demand. Management has invested significantly over several years to build a scalable ingredients platform with sufficient capacity and capabilities for future growth.
  • Shanks remains a key strategic component of the ingredients platform due to its underutilized capacity, technical capabilities, and role in supporting innovation, even after the goodwill impairment. A leadership-level organizational realignment has been implemented at Shanks to strengthen commercial execution, improve facility utilization, and boost operational and financial efficiency.

• Sustainability Progress

  • Universal advanced from an A- to an A rating in the Carbon Disclosure Project (CDP) supplier engagement assessment during Q4 fiscal 26.
  • The company was recognized as a CDP Supplier Engagement Leader and named to CDP's Supplier Engagement A List, highlighting the strength of its emissions governance, emissions management, and supplier collaboration practices.

• Financial Discipline and Capital Structure

  • As of March 31, 2026, net debt stood at $845 million, up from $817 million year-over-year, with the increase driven by higher working capital needs associated with purchasing and processing a significantly larger tobacco crop.
  • Total liquidity availability (including cash and access to committed and uncommitted credit lines) totaled over $1.2 billion as of quarter-end.
  • Universal announced its 56th consecutive annual dividend increase, demonstrating the company's commitment to returning value to shareholders.

1. Tobacco Segment

• Fourth quarter fiscal 26: Revenue of $632 million, up 3% year-over-year; operating income of $27 million, down from $46 million YoY. Contributed 88.4% of total Q4 consolidated revenue.
• Full fiscal year 26: Revenue of $2.6 billion, down slightly from fiscal 25; operating income of $212 million, down from $240 million YoY. Contributed 89.7% of total full-year consolidated revenue.
• Lower operating income was driven primarily by higher inventory write-downs ($43 million full year 26, up from $19 million fiscal 25 and a 5-year average of $14 million) for non-wrapper dark air-cured tobacco.

1. Ingredients Segment

• Fourth quarter fiscal 26: Revenue of $83 million, down from $90 million YoY; operating income of $2 million, down from $4 million YoY. Contributed 11.6% of total Q4 consolidated revenue.
• Full fiscal year 26: Revenue of $348 million, up 3% YoY; operating income of $3 million, down from $12 million YoY. Contributed 12.0% of total full-year consolidated revenue.
• The FruitSmart and Silva sub-businesses performed in line with expectations, while the Shanks sub-business dragged down overall segment results due to higher fixed and operating costs from recent growth investments and delayed new product pipeline commercialization, resulting in a $41 million noncash goodwill impairment charge in fiscal 26.

• Management expects uncommitted tobacco inventory to fall within the target range of 10% to 20% during fiscal 27, and notes that meaningful inventory reduction has already occurred in the two months after the March 31, 2026 quarter-end.
• No material change to the company's long-standing four-pillar capital allocation strategy: 1) investing in growth for the core leaf tobacco business; 2) maintaining and growing the company's strong dividend; 3) pursuing growth opportunities for the plant-based ingredients business; 4) returning excess capital to shareholders via share repurchases.
• Near-term capital allocation will prioritize organic execution of the existing ingredients platform, specifically improving performance and leverage the existing capacity and investments at Shanks, before pursuing new accretive acquisition opportunities for ingredients growth.
• Management confirms confidence that the leaf tobacco business is positioned to navigate ongoing global oversupply and large crop volumes in fiscal 27 with its long-standing operational experience, geographic diversification, and strategic buying strategies, and is encouraged by early season progress.

• There is ongoing oversupply of certain tobacco styles in the global market, which creates pricing and margin pressure for the tobacco segment, especially for non-wrapper dark air-cured tobacco.
• Persistent macroeconomic and industry headwinds in the ingredients market, including ongoing inflationary pressures and tariff uncertainty, have pressured revenue and profitability for Shanks and the broader ingredients segment, and delayed commercialization of new product lines.
• Converting customer interest in new ingredients offerings to sustained revenue and margin growth is a lengthy process, and Shanks is currently behind on its commercial execution targets amid market headwinds.
• Accounting rules require regular assessment of inventory values at the lower of cost or net realizable value, which could result in additional write-downs if market dynamics for tobacco styles shift further during fiscal 27.
• All forward-looking statements are inherently uncertain, and actual results may differ materially from current expectations due to a range of unforeseen risks, as detailed in the company's SEC filings.

Q: What is the outlook for inventory reduction in fiscal 27, is there additional write-down risk for non-wrapper dark air-cured tobacco, and what are the underlying business trends for flue-cured/burley tobacco and non-Shanks ingredients excluding the one-time charges?

A: Management is confident uncommitted inventory will fall within the 10-20% target range this fiscal year, with meaningful reduction already seen in the two months post quarter-end. After the thorough Q4 write-down process aligned with lower-of-cost-or-net-realizable-value accounting rules, management is comfortable with current inventory valuations given current market dynamics. For flue-cured and burley tobacco, management notes ongoing global oversupply and large crop volumes but is optimistic due to broad geographic diversification, experienced local teams, and greater flexibility to buy the right grades at strategic prices to protect margins. For ingredients excluding Shanks, performance has been solid, and lower tariffs could reduce inflationary pressure on customers and create volume growth opportunities in fiscal 27.

Q: What are Universal's current capital allocation priorities, and how will the balance be split between the dividend, deleveraging, and ingredients investment in the coming year?

A: The company's 4-pillar capital allocation strategy introduced in 2018 has not changed: invest in leaf tobacco growth, grow the dividend, pursue ingredients growth opportunities, and return excess capital via share repurchases. While the current year's dividend payout ratio exceeds 100% of reported net income due to one-time charges, the 5-year average payout ratio on adjusted net income remains below 75%, so management and the board see no reason to change the dividend commitment. For ingredients, the current priority is organic execution and delivering returns on prior investments at Shanks, rather than new M&A; new growth opportunities will be pursued once Shanks improves performance and leverages its existing cost base.

Q: How will Diel's experience with Universal's ingredients rollout shape his work as CFO, and what is the long-term value proposition of the ingredients platform?

A: Diel's top priority as CFO is maximizing long-term shareholder value via profitable growth, regulatory compliance, and optimized capital allocation. He plans to focus on four core areas: upholding strong financial stewardship for compliance and reporting; driving continuous improvement in forecasting, cost management, and capital decision making; partnering with the CEO and board to execute the existing strategy of optimizing tobacco, growing ingredients, and supporting the dividend; and clearly communicating Universal's unique positioning to investors. The company is uniquely positioned as a proven market-leading leaf tobacco business with a growing, well-positioned ingredients platform set for long-term value creation.